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Abstract 
Background: Breast cancer (BC) is the most frequent malignancy among females worldwide. Despite several efforts 
and improvements in early diagnosis and treatment, there are still tumors characterized by an aggressive behav-
ior due to unfavorable biology, thus quite difficult to treat. In this view, searching for novel potential biomarkers is 
mandatory. Among them, in the recent years data have been gathered addressing ion channel as important players in 
oncology.
Methods: A retrospective pilot study was performed on 40 BC samples by means of immunohistochemistry in order 
to evaluate hERG1 potassium channels expression in BC.
Results: We provide evidence that hERG1 is expressed in all the BC samples analyzed. hERG1 expression was sig-
nificantly associated with molecular subtype with the highest expression in Luminal A and the lowest in basal-like 
tumors (p = 0.001), tumor grading (the highest hERG1 expression in well-moderate differentiated tumors, p = 0.020), 
estrogen receptors (high hERG1 expression in ER-positive samples, p = 0.008) and Ki67 proliferative index (high 
hERG1 scoring in samples with low proliferative index, p = 0.038). Also, a p value close to significance was noticed for 
the association between hERG1 and HER2 expression (p = 0.079). At the survival analysis, patients with high hERG1 
expression turned out to have a longer progression-free survival, although statistical significance was not reached 
(p = 0.195). The same trend was observed analyzing local relapse free-survival (LRFS) and metastases-free survival 
(MFS): patients with higher hERG1 scoring had longer LRFS and MFS (p = 0.124 and p = 0.071, respectively).
Conclusions: The results of this pilot study provide the first evidence that the hERG1 protein is expressed in primary 
BC, and its expression associates with molecular subtype. hERG1 apparently behaves as a protective factor, since it 
contributes to identify a subset of patients with better outcome. Overall, these data suggest that hERG1 might be an 
additional tool for the management of BC, nevertheless further investigations are warranted to better clarify hERG1 
role and clinical usefulness in BC.
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Background
Breast cancer (BC) is the most frequent malignancy 
among females worldwide [1]. Unfortunately, its inci-
dence is still increasing, particularly in developing coun-
tries [2, 3] and it has been predicted to keep growing at 
least until 2050 [4]. Although 1 in 8 women can experi-
ence this fearful event in their lifetime in Western coun-
tries [5], mortality has been decreasing [1, 6]. Screening 
protocols, early diagnosis, surgery and adjuvant therapy 
(chemotherapy, biological therapies and radiotherapy) 
have greatly contributed to this achievement. A key to 
success in this battle has also been the understanding 
of the biological nature of BC. Nowadays, not only the 
TNM stage but also the identification of the biologi-
cal subtype is crucial in the clinical management of BC. 
The use of endocrine therapy, chemotherapy drugs regi-
mens, monoclonal antibodies, and kinase inhibitors are 
mostly driven by specific biomarkers. Such biomarkers 
can easily be defined by immunohistochemistry (IHC). 
In particular, expression of estrogen receptor (ER), pro-
gesterone receptor (PgR), Ki67 proliferative index, and 
HER2 status, form the basis of the most commonly used 
four pathological subtypes. Such a classification scheme 
is convenient and helpful in guiding clinicians to choose 
appropriate therapy options [7]. However, several con-
cerns still remain in the clinical management of BC. First, 
BC is still misdiagnosed in around 4% of cases [8]. Sec-
ond, there is no target therapy for the cases of basal-like 
BC. Third, systemic therapies often have undesirable side 
effects and limited time of effectiveness due to onset of 
drug resistance [9]. Consequently, additional functional 
biomarkers are strongly needed.
In the last 20  years, ion channels have been proven 
to be novel biomarkers in cancer (reviewed in [10]), 
as well as novel targets for cancer therapy, due to their 
easy druggability [11]. Among ion channels expressed in 
BC, particular attention has been focused on  K+ chan-
nels, both voltage dependent (Kv10.1, Kv1.3, hERG1) 
and  Ca2+-activated (KCa1.1, KCa2.1, KCa2.2, KCa2.3, 
KCa3.1). All these channels are overexpressed in primary 
BC and cell lines, and several correlations with clinico-
pathological features have been demonstrated. In par-
ticular, in primary samples it was shown that KCa1.1 
channels are positively correlated to ER expression [12], 
the occurrence of brain metastases [13], high stage, 
nuclear grade, proliferation and poor prognosis [14].
Among ion channels dysregulated in cancer, the volt-
age-gated  K+ channel hERG1 was shown to be over-
expressed in neoplastic cell lines and human primary 
tumors (reviewed in [15]). hERG1 overexpression was 
demonstrated in many solid cancers, from esopha-
geal [16, 17] to gastric [18] and colorectal cancers [19–
22], and several associations with clinico-pathological 
parameters and outcome were shown. As regards BC, 
most of the available evidences for  K+ channels come 
from in vitro studies. hERG1 has been shown to induce 
cell senescence [23] as well as to mediate the transcrip-
tion of  p21waf/cip in BC cells [24]. Although the analysis 
of public datasets reported the overexpression of the 
hERG1 encoding gene (KCNH2) in BC [25], no studies 
on primary BC reporting clinical correlations according 
to hERG1 protein expression have been published so far.
In the present paper we evaluated the IHC-based 
hERG1 expression profile in a cohort of BC specimens 
and analyzed associations with molecular and clinico-
pathological features.
Materials and methods
Retrospective study on human samples
Pathological evaluation
Every case of BC was diagnosed by two breast patholo-
gists (SB, VV). Cancer molecular subtype was deter-
mined by ER, PgR and HER2 status, according to the 15th 
St. Gallen International Breast Cancer Conference, 2017, 
as follows:
1) Luminal A: ER+ and/or PgR+, HER2−, low Ki67. 
Luminal A tumors are generally low-grade, grow 
slowly and have a favorable prognosis;
2) Luminal B: ER+ and/or PgR+, HER2−, high Ki67 
or ER+ and/or PgR+, HER2+, any Ki67. Luminal B 
tumors grow faster than Luminal A and have a worse 
prognosis;
3) HER2-enriched: ER−, PgR−, HER2+. HER2-
enriched tumors grow faster than luminal cancers 
and generally have a worse prognosis, although 
they can be treated with targeted therapies directed 
against the HER2 protein (trastuzumab, pertuzumab, 
lapatinib and T-DM1 or ado-trastuzumab emtan-
sine).
4) Basal-like (also known as “triple negative”): ER−, 
PgR−, HER2−. Basal-like tumors are characterized 
by the worst prognosis since they are the hardest to 
treat.
Hormone receptor status was reported as negative 
when < 1% of tumors cells stained at IHC. HER2 status 
was determined only by IHC in cases scored as 0 or 1+ 
(negative) and 3+ (positive). Fluorescence in situ hybridi-
zation (FISH) was used in 2+ cases.
Sample collection
A retrospective study was carried out on a set of 40 
BC samples (belonging to patients with median age 
53.5  years, range 28–87  years) of different pathologi-
cal subtype collected from the archives of the Section 
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of Pathological Anatomy, Department of Surgery and 
Translational Medicine, University of Florence-Azienda 
Ospedaliero-Universitaria Careggi, Florence, after 
informed written consent. All the samples belonging 
to Luminal B subtype were HER2 positive. Patients 
underwent surgery at Breast Surgery Unit, Depart-
ment of Oncology, Azienda Ospedaliero-Universitaria 
Careggi, Florence. Data concerning follow up were 
retrieved from the database of the Radiation Oncology 
Unit, Department of Oncology-University of Florence, 
Azienda Ospedaliero-Universitaria Careggi, Florence, 
where takes place patients clinical follow up. In particu-
lar, the following parameters were taken into account: 
presence of local relapse, presence of distant metasta-
ses, progression of the disease, survival.
IHC and scoring of the staining
IHC was performed on formalin-fixed, paraffin-
embedded samples using the anti-hERG1 monoclonal 
antibody (Dival Toscana Srl) at a final dilution 1:500 
following the protocol already published—by Lastraioli 
E et al. [21].
Immunostaining was carried out with a commer-
cially available kit (PicTure-Max polymer Detection kit, 
Invitrogen) according to manufacturer’s instructions. 
hERG1 expression was evaluated by an IHC-based score 
obtained through the combination of the estimate of 
the percentage of immunoreactive cells (quantity score) 
with the estimate of staining intensity (staining intensity 
score). Staining intensity was rated on a scale of 0–3, with 
0 = negative; 1 = weak; 2 = moderate, and 3 = strong. The 
raw data were converted to the complete score by mul-
tiplying the “quantity” and “staining intensity” scores. 
The combined score was as follows: “Score 0”: total 
score = 0; “Score 1”: total score = 1–100; “Score 2”: total 
score = 101–200; “Score 3”: total score = 201–300. Sam-
ples were evaluated by two independent investigators (SB 
and EL).
Statistical analysis
The presence of association between demographic, clini-
cal and biological characteristics as well as the associa-
tion between biomarkers’ expression was evaluated by 
Fisher’s exact test (two-tailed, p < 0.05). The Pearson cor-
relation coefficient (R) was calculated to evaluate rela-
tionships between continuous variables (R = − 1 negative 
relationship, R = 0 no relationship, R = 1 positive rela-
tionship). Survival analyses were performed applying Log 
Rank Test and Kaplan–Meier plots. Statistical analyses 
were performed using Stata 9.1 (StataCorp, TX, USA) 
and Microcal Origin 9.0 (OriginLab, MA, USA).
Results
hERG1 is expressed in BC primary samples
Forty primary BC samples were retrospectively studied 
by IHC to assess hERG1 expression. Overall, hERG1 was 
expressed in 100% of BC samples. According to the scor-
ing system applied (see “Materials and methods”), 7.5% of 
the samples were scored as Score 1, 30.0% showed a mod-
erate hERG1 expression (Score 2) and 57.5% had a very 
high hERG1 expression (Score 3). Representative pictures 
of the IHC performed with the anti-hERG1 monoclonal 
antibody (see “Materials and methods”), relative to each 
score, are reported in Fig.  1 together with the corre-
sponding Hematoxylin–Eosin microphotographs.
Dividing the samples according to molecular subtype, 
it emerged that hERG1 scoring was higher in Luminal A 
and B samples (100 and 66.7%, respectively, of the sam-
ples were scored as “3”) with respect to HER2+ and 
basal-like samples, in which 50 and 20% of the samples 
were scored as “3”(Fig. 1d).
Associations with molecular and clinico‑pathological 
parameters
Data gathered from IHC experiments were analyzed 
through Fisher Exact test and several associations 
emerged (Table  1). Interestingly, hERG1 scoring was 
associated with molecular subtype (p = 0.001) being 
higher in Luminal A, progressively decreasing in Luminal 
B, HER2+ and basal-like tumors. We also found an asso-
ciation with grading, with higher scoring in G1 and G2 
samples (p = 0.020). Moreover, hERG1 scoring was signif-
icantly associated with ER expression, with higher hERG1 
scoring in ER-positive samples (p = 0.008), and inversely 
associated with Ki67 (higher hERG1 scoring in samples 
with Ki67 index lower to 15%, p = 0.038). Finally, an 
inverse association with HER2 expression emerged, with 
the highest hERG1 expression in HER2 negative samples, 
whose p value (0.079) was close to be significant. Since 
in the HER2+ group (composed of samples with HER2 
scoring = 3) hERG1 expression was unequally distributed 
(see Table 1), we analyzed the percentage of positive cells 
per microscopic field applying the Pearson correlation 
coefficient and we found that the correlation between the 
two proteins was weak (R = 0.118), in accordance with 
the results of Fisher’s Exact Test (p = 0.079).
Survival analyses
Since the study was retrospective, all the patients had a 
long follow up. Overall Survival was not performed, since 
all the patients were alive at the end of the study. Thus, 
we performed survival analyses to evaluate progression-
free survival (PFS), local relapse-free survival (LRFS) 
and distant metastases-free survival (DMFS). From 
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such analyses it emerged that patients with high hERG1 
expression had a longer LRFS and PFS, although statisti-
cal significance was not reached (p = 0.124 and p = 0.195, 
respectively). When performing a survival analysis taking 
into account metastases-free survival (MFS) it emerged a 
similar trend, since patients with higher hERG1 scoring 
had longer MFS, with a p value close to the significance 
(p = 0.071).
Kaplan–Meier plots of PFS, LRFS and DMFS according 
to hERG1 scoring are in Fig. 2.
Discussion
In the present paper we provide evidence that hERG1 
potassium channels are expressed in BC and positively 
affect patients’ prognosis. Data presented here are the 
results of a pilot study performed on 40 BC primary 
samples from which we showed that hERG1 protein is 
expressed in a high percentage of samples belonging to 
all the four molecular subtypes. To our knowledge this 
is the first demonstration of the association of hERG1 
channels with BC molecular subtypes. These findings 
open new perspectives for BC management, since basal-
like BC include most of triple negative BC, that do not 
express ER, PgR and HER2 being therefore the hardest 
to treat: in this scenario, hERG1 presence might be help-
ful for targeted therapies. When dealing with basal-like 
BC, it is worth noting that several subgroups have been 
identified, taking into account genomic instability and 
rearrangements (reviewed in [26]), and it gets the man-
agement of such disease more complicated. To ensure 
the best treatment option for each patient, the concept 
of “personalized” or “tailored” therapies was particularly 
emphasized at the 2017 St. Gallen International Expert 
Consensus.
Also more interestingly, we showed here that hERG1 
is highly expressed in samples characterized by positive 
prognostic features such as Luminal A molecular sub-
type, well and moderately differentiated tumors (G1 and 
G2), low proliferation rate (Ki67 index ≤ 15%). Also, a 
borderline association was noticed when analyzing HER2 
scoring, with the highest hERG1 expression in HER2 
negative samples (characterized by better prognosis). 
Overall, these findings are in accordance with the results 
we obtained from survival analyses and a trend emerged 
addressing hERG1 as a protective factor, positively affect-
ing BC in terms of PFS, LRFS and DMFS. The data we 
gathered from the present study fit well in the context 
described in a paper published in 2013 [27], in which an 
“IC30 gene signature” composed of 30 ion channel genes 
was defined and proven to be a prognostic marker in BC, 
independently of clinical and pathological prognostic 
factors.
Fig. 1 IHC and scoring system assessment for hERG1 in the different 
molecular subtypes. a–c Hematoxylin–Eosin staining (right panels) 
and IHC (left panels) of representative samples. a Score 1. b Score 2. 
Score 3 (d). No primary antibody (negative control). IHC procedures 
and scoring assessment were performed according to what reported 
in the “Materials and methods” section. Original magnification 
×200. Scale bar: 100 μm. e Histogram summarizing hERG1 levels 
of expression in the four different pathological subtypes of breast 
cancer evaluated by IHC. White bars: Score 1, Grey bars: Score 2, Black 
bars: Score 3
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Our findings might add an element to the complex pic-
ture of BC, delineated over the last years. In fact, even 
using extensive genomic profiling four coherent groups 
similar to the intrinsic subtypes emerge as stated in the 
2015 St. Gallen Consensus Conference [28]. From this 
perspective the greatest controversies arise in using or 
not chemotherapeutic agents in “luminal” cases with hor-
mones receptors positivity and negative HER2, which can 
display very different clinical behaviors. Another group 
of patients needing a deeper investigation is indeed the 
triple-negative. Again with the St. Gallen 2015 panel 
members’ words, we could state that “further dissection 
of subtypes within triple-negative breast cancer reveals 
seven distinct groupings, which differ markedly in their 
clinical response to neoadjuvant chemotherapy [29]. 
Preclinical studies also show heterogeneity of response 
to other agents in cell lines of the different triple-nega-
tive subtypes [30]”. In both these two groups, genotyp-
ing has partially answered to the need of this further 
characterization [26, 31] and nowadays several com-
mercial kits (i.e. ONCOTYPE  DX®,  MAMMAPRINT®, 
 BLUEPRINT®,  TARGETPRINT®,  PROSIGNA®) that can 
be used to analyze a different number of genes set and 
better define the biological essence of every single case 
are available. Knowledge of specific genes and their prod-
ucts, implicated in BC tumorigenesis, has proved to be of 
utmost importance in BC cure.
The clinical utility of the addition of the 70-gene 
signature test  (MammaPrint®) to standard clinical-
pathological criteria in selecting patients for adjuvant 
chemotherapy was largely demonstrated by the recently 
published MINDACT trial (ClinicalTrials.gov number, 
NCT00433589; EudraCT number, 2005-002625-31). 
This randomized, phase 3 study, evaluated different 
adjuvant approaches on 6693 women affected by early-
stage breast cancer basing on their genomic (using the 
70-gene signature) and clinical  risk (using a modified 
version of Adjuvant! Online). Among women at high 
Table 1 Associations between hERG1 expression and molecular and clinicopathological parameters
* p < 0.05 (Fisher Exact Test)
hERG1 score 0 hERG1 score 1 hERG1 score 2 hERG1 score 3 p value
Molecular subtype
 Luminal A 0 (0%) 0 (0%) 0 (0%) 11 (100%) 0.001*
 Luminal B 0 (0%) 0 (0%) 3 (33.3%) 6 (66.7%)
 HER2+ 0 (0%) 2 (20%) 3 (30%) 5 (50%)
 Basal-like 0 (0%) 1 (10%) 7 (70%) 2 (20%)
Grading
 G1 0 (0%) 0 (0%) 0 (0%) 6 (100%) 0.020*
 G2 0 (0%) 0 (0%) 0 (0%) 6 (100%)
 G3 0 (0%) 3 (10.7%) 13 (46.4%) 12 (42.9%)
TNM stage
 I 0 (0%) 1 (4.3%) 7 (30.4%) 15 (65.2%) 0.071
 II 0 (0%) 1 (11.1%) 5 (55.6%) 3 (33.3%)
 III 0 (0%) 0 (0%) 1 (14.3%) 6 (85.7%)
 IV 0 (0%) 1 (100%) 0 (0%) 0 (0%)
ER
 Negative 0 (0%) 3 (15.8%) 9 (47.4%) 7 (36.8%) 0.008*
 Positive 0 (0%) 0 (0%) 4 (19.1%) 17 (80.9%)
PgR
 Negative 0 (0%) 3 (12.5%) 10 (41.7%) 11 (45.8%) 0.083
 Positive 0 (0%) 0 (0%) 3 (18.7%) 13 (81.2%)
HER2
 Negative 0 (0%) 1 (7.7%) 7 (53.8%) 5 (38.5%) 0.079
 Score 1 0 (0%) 0 (0%) 0 (0%) 7 (100%)
 Score 2 0 (0%) 0 (0%) 0 (0%) 0 (0%)
 Score 3 0 (0%) 2 (10%) 6 (30%) 12 (60%)
Ki67
 ≤15% 0 (0%) 0 (0%) 0 (0%) 8 (100%) 0.038*
 >15% 0 (0%) 3 (9.4%) 13 (40.6%) 16 (50%)
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clinical risk and low genomic risk for recurrence, the 
receipt of no chemotherapy on the basis of the 70-gene 
signature led to a 5-year rate of survival without dis-
tant metastasis that was 1.5% points lower than the 
rate with chemotherapy, showing that around 46% of 
women with breast cancer who are at high clinical risk 
might not require chemotherapy [32].
Unfortunately, this is an expensive task, which can-
not be reproduced on a routinely basis in most Public 
Health Systems. Therefore, the search for surrogate bio-
molecular markers is definitely worth to be carried on in 
the BC scenario, since this can translate is useful prog-
nostic and therapeutic tools for clinicians. Among bio-
molecular markers, stemness markers represent a novel 
and interesting tool for the management of different 
kind of tumors [33]. In BC it was shown that cancer stem 
cells correlate with disease progression and prognosis 
in in vivo models [34]. More recently, Finicelli et al. [35] 
demonstrated that the stem cell marker SOX2 is an inde-
pendent factor to predict early recurrence in BC.
A recently published review [36] summarized the 
identified biomarkers of TNBC that comprise basal-like 
BC, although the two categories are not exactly identi-
cal and overlapping. Some molecules are overexpressed 
in TNBC, although not exclusive of this subgroup of 
BC, and could therefore serve as biomarkers for this 
subgroup of BC (i.e. EGFR, Ki67, VEGF-A, p53). In par-
ticular, it was shown that EGFR expression is related 
to the aggressiveness of the disease and poor response 
to chemotherapy [37], and it was proposed that EGFR 
might be used for the differential classification of basal-
like BC. These findings are of particular interest within 
our research field, since we demonstrated that hERG1 
channel expression is significantly associated with EGFR 
expression in pancreatic ductal adenocarcinomas [38] 
and colorectal cancers [21]. This association might be 
exploited also for therapy purposes, since EGFR is a tar-
get of cetuximab that might be used in combination with 
specific anti-hERG1 drugs. A similar approach might be 
applied to VEGF-A whose high expression is associated 
with poor prognosis [36]: in fact, we showed that in colo-
rectal [21] and gastric [18] cancers hERG1 expression is 
significantly associated with VEGF-A expression and the 
combined therapy with bevacizumab and hERG1 block-
ers impairs tumor growth in mouse models [18]. More 
recently it was also shown that hERG1 interaction with 
β1 integrins mediates BC metastatization in immunode-
ficient mice [39].
Conclusion
Data reported in the present paper, although prelimi-
nary, open new promising perspectives for BC manage-
ment, and the inhibitors of the channels might be used 
for combined therapy together with EGFR and VEGF-
A blockers. The results of this pilot study indicate that 
hERG1 expression is associated with clinical-pathological 
features in BC and it behaves as a positive factor thus it 
might be an additional tool for the management of BC. 
Nevertheless, further investigations are warranted to bet-
ter clarify hERG1 role and usefulness in BC.
Fig. 2 Kaplan Meier plots according to hERG1 scoring. a PFS; b LRFS; 
c DMFS. Blue curves: hERG1 negative samples (Score ≤ 150), red 
curves: hERG1 positive samples (Score > 150)
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